Want to see IN:SOLARA full AI Analyst Report?
Top Page
Solara Active Pharma Sciences Ltd.
(SOLARA)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹622.00
▲(26.85% Upside)
Action:Reiterated
Date:09/08/26
The score is held back primarily by weak and volatile fundamentals: inconsistent profitability (FY2026 net loss), sharp gross-margin swings, and a major drop in free cash flow in FY2026. Technicals are a positive offset with a clear uptrend and strong MACD momentum, but overbought readings (RSI/Stoch) raise near-term risk. Valuation is also a drag due to the negative P/E and lack of a reported dividend yield.
Positive Factors
Revenue Recovery
The return to revenue growth indicates that Solara regained commercial momentum after a stagnant prior year. Continued expansion in API sales and related manufacturing activity could improve operating leverage and provide a stronger base for earnings recovery over the next several quarters.
Negative Factors
Persistent Net Loss
The continued net loss shows that improved operating performance has not yet translated into sustainable bottom-line profitability. Until Solara consistently earns positive net income, its ability to fund growth internally and generate dependable shareholder returns remains constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The return to revenue growth indicates that Solara regained commercial momentum after a stagnant prior year. Continued expansion in API sales and related manufacturing activity could improve operating leverage and provide a stronger base for earnings recovery over the next several quarters.
Read all positive factors
Solara Active Pharma Sciences Ltd. (SOLARA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹31.12B
Dividend Yield0.45%
Average Volume (3M)28.02K
Price to Earnings (P/E)84.0
Beta (1Y)0.82
Revenue Growth27.30%
EPS Growth456.80%
CountryIN
Employees1,669
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.56
Shares Outstanding48,070,286
10 Day Avg. Volume30,281
30 Day Avg. Volume28,019
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Solara Active Pharma Sciences Ltd. Business Overview & Revenue Model
Company Description
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing,...
How the Company Makes Money
Solara makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to pharmaceutical companies that formulate and commercialize finished drug products. Revenue is generated from (1) API sales, where Solara supplies ...
Solara Active Pharma Sciences Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
58
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.31B | 13.69B | 12.84B | 12.89B | 14.27B | 12.68B |
| Gross Profit | 4.52B | 3.66B | 6.57B | -1.30B | 1.25B | 5.60B |
| EBITDA | 1.94B | 1.87B | 2.06B | -2.82B | 1.53B | 863.30M |
| Net Income | -16.20M | -74.10M | 5.40M | -5.67B | -221.70M | -581.50M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 23.33B | 22.32B | 23.51B | 28.99B | 29.53B |
| Cash, Cash Equivalents and Short-Term Investments | 533.40M | 533.40M | 41.10M | 84.40M | 87.30M | 463.80M |
| Total Debt | 0.00 | 6.87B | 7.96B | 10.12B | 10.13B | 10.37B |
| Total Liabilities | -12.56B | 10.77B | 11.35B | 14.14B | 13.97B | 14.18B |
| Stockholders Equity | 12.56B | 12.53B | 10.94B | 9.34B | 15.00B | 15.25B |
Cash Flow | ||||||
| Free Cash Flow | 454.60M | 88.80M | 1.73B | 678.10M | 449.40M | -4.51B |
| Operating Cash Flow | 740.60M | 617.00M | 2.13B | 1.09B | 1.56B | -2.42B |
| Investing Cash Flow | -273.60M | -998.60M | -368.30M | -35.10M | -811.40M | -2.43B |
| Financing Cash Flow | -469.60M | 386.90M | -1.80B | -1.06B | -1.13B | 3.34B |
Solara Active Pharma Sciences Ltd. Technical Analysis
Negative
490.35
Price Trends
656.68
Negative
604.84
Positive
553.07
Positive
Market Momentum
-9.50
Positive
39.31
Neutral
40.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SOLARA, the sentiment is Negative. The current price of 490.35 is below the 20-day moving average (MA) of 684.09, below the 50-day MA of 656.68, and below the 200-day MA of 553.07, indicating a neutral trend. The MACD of -9.50 indicates Positive momentum. The RSI at 39.31 is Neutral, neither overbought nor oversold. The STOCH value of 40.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SOLARA.
Solara Active Pharma Sciences Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹94.91B | 15.40 | ― | 0.49% | 7.28% | 68.82% | |
64 Neutral | ₹199.87B | 29.85 | ― | 0.22% | 24.83% | 36.88% | |
64 Neutral | ₹51.25B | 30.46 | ― | 0.57% | 18.56% | 60.06% | |
56 Neutral | ₹26.02B | -76.92 | ― | 0.28% | -5.37% | -153.40% | |
56 Neutral | ₹35.44B | 11.66 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹31.12B | 83.97 | ― | 0.45% | 27.30% | 456.80% |
* General Sector Average
IN:SOLARA
Solara Active Pharma Sciences Ltd.
618.65
24.50
4.12%
IN:GRANULES
Granules India Limited
816.80
258.61
46.33%
IN:HIKAL
Hikal Limited
202.85
-40.71
-16.72%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
171.50
77.72
82.88%
IN:STAR
Strides Pharma Science Ltd
998.05
183.81
22.57%
IN:UNICHEMLAB
Unichem Laboratories Limited
488.15
22.10
4.74%
Solara Active Pharma Sciences Ltd. Corporate Events
Solara Tightens KYC Norms for Physical Shareholders Under SEBI Mandate
Sep 26, 2026
Solara Active Pharma Sciences Ltd., a listed pharmaceutical company specializing in active pharmaceutical ingredients, is tightening compliance for investors who still hold shares in physical form. The move reflects broader regulatory efforts in I...
Solara Active Pharma Files Sustainability Report for FY 2025-26
Aug 25, 2026
Solara Active Pharma Sciences Limited has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year, covering operations from April 1, 2025 to March 31, 2026. The report is filed under SEBI’s listing regu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.